Abciximab contraindications: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) |
Gerald Chi (talk | contribs) |
||
| Line 13: | Line 13: | ||
* Administration of oral [[anticoagulant]]s within seven days unless [[prothrombin time]] is <1.2 times control | * Administration of oral [[anticoagulant]]s within seven days unless [[prothrombin time]] is <1.2 times control | ||
* [[Thrombocytopenia]] (<100 000 cells/m L) | * [[Thrombocytopenia]] (<100 000 cells/m L) | ||
* Recent (within six weeks) major surgery or [[trauma]] | * Recent (within six weeks) major [[surgery]] or [[trauma]] | ||
* Intracranial neoplasm, [[arteriovenous malformation]], or [[aneurysm]] | * Intracranial [[neoplasm]], [[arteriovenous malformation]], or [[aneurysm]] | ||
* Severe uncontrolled [[hypertension]] | * Severe uncontrolled [[hypertension]] | ||
* Presumed or documented history of [[vasculitis]] | * Presumed or documented history of [[vasculitis]] | ||
Revision as of 17:16, 30 January 2014
Template:Abciximab Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2], Pratik Bahekar, MBBS [3]
Contraindications
Because Abciximab may increase the risk of bleeding, Abciximab is contraindicated in the following clinical situations:
- Active internal bleeding
- Recent (within six weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of clinical significance.
- History of cerebrovascular accident (CVA) within two years, or CVA with a significant residual neurological deficit
- Bleeding diathesis
- Administration of oral anticoagulants within seven days unless prothrombin time is <1.2 times control
- Thrombocytopenia (<100 000 cells/m L)
- Recent (within six weeks) major surgery or trauma
- Intracranial neoplasm, arteriovenous malformation, or aneurysm
- Severe uncontrolled hypertension
- Presumed or documented history of vasculitis
- Use of intravenous dextran before PCI, or intent to use it during an intervention
- Abciximab is also contraindicated in patients with known hypersensitivity to any component of this product or to murine proteins.[1]
References
Adapted from the FDA Package Insert.